Month: May 2024

First-quarter net revenue of $70.7 million First-quarter gross margin of 20.2% and Variable Marketing Margin (VMM) of 23.7%CLEARWATER, Fla., May 15, 2024 (GLOBE NEWSWIRE) — Digital Media Solutions, Inc., (OTCMKTS: DMSL) (“DMS” or the “Company”), a leading provider of technology-enabled digital performance advertising solutions connecting consumers and advertisers, today announced financial results for the first quarter ended March 31, 2024. DMS serves over 315 scaled enterprise customers and approximately 4,550 small and medium-sized businesses across the Property and Casualty (P&C) Insurance, Health Insurance, Ecommerce, Career and Education and Consumer Finance verticals with digital performance marketing solutions. “Our first quarter results again reflected improving conditions in the Property and Casualty vertical,...

New York, NY, May 15, 2024 (GLOBE NEWSWIRE) — Interpublic Group (NYSE: IPG) senior management will present at the 52nd Annual J.P. Morgan Global Technology, Media and Communications Conference on Monday, May 20th, 2024, at 10:00 am Eastern time, as scheduled. A link to the live webcast will be posted on the day of the conference on the Investor Relations section of Interpublic’s website (http://investors.interpublic.com) where it will remain available for replay for 30 days. # # # About InterpublicInterpublic (NYSE: IPG) (www.interpublic.com) is a values-based, data-fueled, and creatively-driven provider of marketing solutions. Home to some of the world’s best-known and most innovative communications specialists, IPG global brands include Acxiom, Craft, FCB, FutureBrand, Golin, Huge, Initiative, IPG Health, IPG Mediabrands,...

Jeffrey S. Humphrey, MD appointed Chief Medical Officer;Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Jeffrey S. Humphrey, MD has been appointed Chief Medical Officer (CMO) and Jean-Claude Provost, MD has been named Chief Science Officer (CSO), effective May 28, 2024. “Jeff’s clinical oncology expertise and leadership will bring immense value to Lantheus as we strengthen our position as the leading radiopharmaceutical-focused company through sustained innovation in diagnostics and therapeutics,” said Brian Markison, Chief Executive Officer, Lantheus. “Jean-Claude’s...

HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2024 Annual Meeting of Stockholders will take place on August 27, 2024, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is July 1, 2024. About FibroBiologicsBased in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds...

Conference Call Scheduled for today, May 15, 2024, at 5:00pm ET GARDNER, Mass., May 15, 2024 (GLOBE NEWSWIRE) — Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its third quarter fiscal year 2024 for the period ended March 31, 2024. Q3 2024 Financial Highlights (3 Months Ended March 31, 2024):Revenue increased 4% to $5.2 million, compared to $5.0 million in the same quarter of the previous fiscal year, and up 9% compared to the most recent sequential quarter. Engineering revenue increased 62% to $2.3 million compared to $1.4 million in the same quarter of the previous fiscal year, representing record engineering revenue. Production revenue was $3.0 million compared...

A CONFERENCE CALL IS SCHEDULED FOR THURSDAY, MAY 16, 2024, 11:00AM EASTERN TIME SEE DIAL IN NUMBER BELOW VICTORIA, BRITISH COLUMBIA, May 15, 2024 (GLOBE NEWSWIRE) — FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE Amex: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. Today the Company announces financial results for first quarter ended March 31, 2024. Mr. Daniel B. O’Brien, CEO, states, “Progress is being made. We streamlined operations by closing our Naperville R&D facility and moving all the work to our Peru, IL building. The exit costs from this action were nearly all taken in Q1...

CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its first quarter 2024, for the period ended March 31, 2024, on Wednesday, May 22, 2024, before market open. The Company has scheduled a conference call for the same day, Wednesday, May 22, 2024, at 9:00 am ET to review the results. Filing of 10-QFollowing today’s filing of a Form 12b-25 with the SEC, the Company expects to file its Form 10-Q on Monday, May 20, 2024. Conference Call Details Date and Time: Wednesday, May 22, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast,...

ELI-002 2P Phase 1 preliminary data published in Nature Medicine ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response and ELI-002-generated antigen spreading presented at the AACR Annual Meeting ELI-002 7P Phase 1 preliminary data to be presented at the ASCO Annual Meeting (“ASCO”) in June 2024 ELI-002 7P randomized Phase 2 trial enrollment expected to complete in fourth quarter 2024BOSTON, May 15, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent corporate and clinical updates. “During the first quarter, we continued to make great...

DALLAS, May 15, 2024 (GLOBE NEWSWIRE) — DallasNews Corporation (Nasdaq: DALN) (the “Company”) today reported a first quarter 2024 net loss of $1.4 million, or $(0.25) per share, and an operating loss of $1.8 million. In the first quarter of 2023, the Company reported a net loss of $2.6 million, or $(0.49) per share, and an operating loss of $2.8 million. For the first quarter of 2024, on a non-GAAP basis, DallasNews reported an operating loss adjusted for certain items (“adjusted operating loss”) of $0.8 million, an improvement of $1.4 million or 64.0 percent when compared to an adjusted operating loss of $2.2 million reported in the first quarter of 2023. The improvement is primarily due to expense savings of $2.5 million in distribution, $1.6 million in employee compensation and benefits, and $0.9 million in newsprint, partially...

15 May 2024 – Alstom’s 2023/24 Universal Registration Document, which includes notably the Annual Financial Report, was filed with the “Autorité des marchés financiers” (AMF) on 15 May 2024. This document is available to the public free of charge in accordance with applicable regulation and may be viewed on Alstom’s website (https://www.alstom.com/finance), as well as on the AMF website (www.amf-france.org). The following information is included in the 2023/24 Universal Registration Document: •the Annual Financial Report, including notably the consolidated financial statements, the statutory accounts, the related Statutory Auditors’ reports and the management report, •the Board of Directors’ report on corporate governance, •the Statutory Auditors’ special report on related-party agreements and...